Cyanosis News and Research

RSS

Cyanosis refers to abnormal blue discoloration of the skin and mucous membranes. The term is derived from the Greek word kuaneos meaning dark blue.

The effect of moderate intensity exercise in pregnant women with cardiovascular disease

Researchers assess the effect of moderate-intensity exercise in pregnant women with cardiovascular disease.

19 Apr 2023

SARS-CoV-2 transmission from infected owner to pet rats

SARS-CoV-2 Omicron transmission from a symptomatically infected individual to two domestic rats.

19 Oct 2022

The role of SARS-CoV-2 in COVID-19-associated chilblains

A recent study published in the British Journal of Dermatology evaluated COVID-19-associated chilblains.

23 Aug 2022

What impact has SARS-CoV-2 variant B.1.1.519 had on Mexico City?

The current study reports the effective reproduction number of B.1.1.519 and presents its geographical origin based on phylogenetic analysis.

20 Sep 2021

Gout drug may improve heart function in individuals with congenital heart disease

A drug used to treat gout, probenecid, may improve heart function in individuals with a particular heart defect, according to results from a small pilot study run by a University of Cincinnati researcher.

27 Aug 2020

Old letters provide insight into Spanish flu pandemic horror

An archive of letters written by those who survived the Spanish flu pandemic at the start of the last century shows what it was actually like to live during that time. The Spanish flu pandemic killed over 250,000 people in Britain alone and worldwide it wiped out a population of over 100 million.

23 Sep 2018

Study sheds new light on underlying genetic causes of congenital heart disease

Approximately one in every 100 babies is born with congenital heart disease (CHD), and CHD remains the leading cause of mortality from birth defects.

9 Oct 2017

Children with single-ventricle disease have higher rates of brain abnormalities at each stage of surgery

As children with single-ventricle disease, a complex and severe heart defect, undergo a series of three reconstructive surgeries, pediatric researchers have detected higher rates of brain abnormalities at each stage.

4 May 2017

Lung cancer surgery patients at higher risk of developing venous thromboembolism

New evidence suggests that lung cancer surgery patients are at higher risk of developing venous thromboembolism, including deep vein thrombosis (DVT) and pulmonary embolism (PE), than previously thought, with elevated risks of complications or death. When thromboemboli occur, they may be asymptomatic or attributed to post-surgical pain or complications, and may reflect both the lung cancer itself as well as compromised lung function after surgery.

29 Apr 2015

Research opens door to new direction of PAH treatment

The development of new, more effective vasodilators to treat pulmonary arterial hypertension has been hampered because of their systemic toxicity and adverse side effects. An international team of investigators seeking to surmount these problems and increase drug efficacy have determined that a vascular homing peptide can selectively target hypertensive pulmonary arteries to boost the pulmonary but not systemic effects of vasodilators. Importantly for potential clinical use, this peptide retains its activity when given sublingually. The results using a rat model of PAH are published in the American Journal of Pathology.

8 Jan 2014

IUSL awarded patent for method for changing perception of skin tone

How someone perceives color is determined by how the item they are looking at scatters and emits light. In August, three City College of New York physicists affiliated with the Institute for Ultrafast Spectroscopy and Lasers (IUSL) were awarded a patent for a method for changing perception of skin tone by applying quantum and optical principles to cosmetic preparations.

6 Nov 2013

Positive new data from Genzyme’s eliglustat tartrate Phase 3 studies on Gaucher disease type 1

Genzyme, a Sanofi company, today announced positive new data from the Phase 3 ENGAGE and ENCORE studies of eliglustat tartrate, its investigational oral therapy for Gaucher disease type 1.

15 Feb 2013

AMAG seeks FDA sNDA approval for Feraheme Injection

AMAG Pharmaceuticals, Inc. today announced that it has submitted a supplemental new drug application (sNDA) to the United States Food and Drug Administration (FDA) for Feraheme (ferumoxytol) Injection for Intravenous (IV) use.

25 Dec 2012

AMAG presents new data from two ferumoxytol phase III trials on IDA at ASH annual meeting

AMAG Pharmaceuticals, Inc. today announced that new data from two pivotal phase III clinical trials were presented at the American Society of Hematology's (ASH) annual meeting in Atlanta, Georgia.

11 Dec 2012

AMAG receives Swiss marketing authorization for ferumoxytol to treat iron deficiency anemia

AMAG Pharmaceuticals, Inc. today announced that the Swiss Agency for Therapeutic Products (Swissmedic) has granted marketing authorization in Switzerland for ferumoxytol, an intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adult patients with chronic kidney disease.

6 Sep 2012

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

AMAG Pharmaceuticals, Inc. today reported preliminary results from the second phase III study from its global registrational program for Feraheme (ferumoxytol) in patients with iron deficiency anemia (IDA) regardless of the underlying cause.

19 Jul 2012

'Blue baby' study sheds light on basic biology

A newborn described as a "happy blue baby" because of her bluish skin color but healthy appearance made a small mark in medical history when one of her physicians discovered something new in her genes-the hemoglobin Toms River mutation.

17 Jun 2011

Treatment with sildenafil significantly reduces RP in patients with scleroderma

Researchers in Europe reported that treatment with modified-release sildenafil significantly reduced the frequency of attacks of Raynaud's phenomenon in patients with limited cutaneous systemic sclerosis, also known as scleroderma.

8 Mar 2011

PHA partners with NORD, EURORDIS to raise global awareness about PH

Pulmonary hypertension is a rare, under-diagnosed disease that can strike people at any time, affecting newborns to the elderly or anyone in between. To raise global awareness of this invisible disease, the Pulmonary Hypertension Association is partnering with the National Organization for Rare Disorders and Rare Diseases Europe on Feb. 28, 2011, to observe Rare Disease Day.

25 Feb 2011

Skin-colored hospital gowns can help detect cyanosis

Changing the hue of hospital gowns and bed sheets to match a patient's skin color could greatly enhance a physician's ability to detect cyanosis and other health-related skin color changes, according to a new study from Rensselaer Polytechnic Institute.

30 Apr 2010